Our team presented a new poster abstract at the NSAP 2019 Annual Meeting and Expo held Sept. 9-12 in Washington, D.C. This poster was a combined effort between CPS and UAB Medicine. Our team, consisting of Matthew Malachowski, PharmD, BCPS, UAB Medicine, Lily Duong, PharmD, RPh, Chief Clincal Officer at CPS, Khang Tran, PharmD, CPS, and Abbas Dewji, PharmD, CPS, presented an all-new study "Coupling Patient Care Management Operations with Technology and Data Platform to Optimize Hepatitis C Therapy Outcomes."
- Chronic hepatitis C viral infection is estimated to affect 2.4 million people in the United States. If left untreated the infection can cause serious liver damage and is currently the leading cause of liver transplants in the US.
- HCV treatment regimens, with the introduction of direct-acting antiviral in recent years, have become simpler, safer, and more effective. Clinical trials have demonstrated sustain virologic response (SVR) rates higher than 90%. However, given the cost of treatment and the importance of adherence in order to achieve and maintain SVR, patients need to be appropriately managed.
- Specialty pharmacies are uniquely suited to optimize therapy and improve the overall journey for hepatitis C patients.
- TherigySTM is a patient-focused specialty therapy management software. The platform equips pharmacies with the tools to standardize patient management programs and to capture value-based outcomes.
To demonstrate the cure rate measurement possible with standardized pharmacy clinical operations supported by a technology platform.
Download the poster by filling out the form below: